NCT00287989View on ClinicalTrials.gov

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

May 31, 2009

Conditions
Lung Cancer
Interventions
DRUG

Carboplatin

DRUG

erlotinib hydrochloride

150mg

DRUG

Paclitaxel

200mg/m2

DRUG

erlotinib hydrochloride

1500mg

Trial Locations (2)

10021

Memorial Sloan-Kettering Cancer Center, New York

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00287989 - Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter